Apellis Pharmaceuticals (APLS) and Sobi said Friday that new data from a phase 3 study showed that Empaveli demonstrated 68% proteinuria reduction that was sustained for one year.
The study evaluated Empaveli, or pegcetacoplan, in patients with kidney diseases C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
According to phase 3 data, patients treated with Empaveli also showed stabilization of kidney function as measured by estimated glomerular filtration rate, the companies said. The product candidate showed favorable safety and tolerability, with no new safety signals observed, the partners added.
Marketing applications for Empaveli are currently under review in Europe and the US, according to the statement.
Shares of Apellis were up more than 1% in recent trading Friday.
Price: 19.34, Change: +0.24, Percent Change: +1.26
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.